Comment: Pirtobrutinib: A New and Distinctive Treatment Option for B-Cell Malignancies

Schultze MD Reeves DJ. Pirtobrutinib: a new and distinctive treatment option for B-cell malignancies [published online ahead of print January 18, 2023]. Ann Pharmacother. doi:10.1177/10600280231223737.

AstraZeneca. Calquence tablet PI, English. Last updated Aug 2022, Accessed March 10, 2024. https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/e2a005a7-65a0-4388-a671-dc887815a938/e2a005a7-65a0-4388-a671-dc887815a938_viewable_rendition__v.pdf.

Astrazeneca. Calquence capsule PI, English. Last updated March 2022, Accessed April 1, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210259s009lbl.pdf.

Sharma S Pepin X Burri H , et al. Bioequivalence and relative bioavailability studies to assess a new acalabrutinib formulation that enables co-administration with proton-pump inhibitors. Clin Pharmacol Drug Dev. 2022;11(11):1294-1307.

AstraZeneca. A study to evaluate relative bioavailability, proton pump inhibitor (PPI) (rabeprazole) effect, food effect and particle size effect of new acalabrutinib tablet in healthy subjects. ClinicalTrials.gov website. Accessed March 10, 2024. https://clinicaltrials.gov/ct2/show/NCT04488016.

AstraZeneca. A study in healthy subjects to assess bioavailability (proportion of a drug which enters the circulation to have an active effect) of acalabrutinib tablet and proton-pump inhibitor effect (members of a class of medications that inhibits in gastric acid production) for rabeprazole. Accessed March 10, 2024. ClinicalTrials.gov website. https://clinicaltrials.gov/ct2/show/NCT04564040. 4. CALQUENCE® (acalabrutinib) Tablets Prescribing Informa.